Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROADSTER: 177Lu-PNT2002 + Brachytherapy for Recurrent Prostate Cancer
NCT05230251Phase 2Completed
- Start
- Mar 2022
- Primary completion
- Sep 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Lu-PNT2002 in prostate cancer (PCa) (2 arms). Primary endpoint: Safety and Efficacy at 24 weeks. Started Mar 2022; status: completed.
02
Drugs
Lu-PNT2002
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05230251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230251.